Abrégé

The present invention relates to a composition comprising L-aspartic acid as an active ingredient for promoting differentiation into myocytes or osteoblasts. It has been confirmed that L-aspartic acid regulates the expression of muscle differentiation markers, inhibits muscle atrophy, and regulates the expression of differentiation markers of osteoblasts, and thus can be advantageously used for preventing, treating, and alleviating muscle diseases, osteogenesis, or diseases requiring promotion of osteogenesis.

Classes IPC  ?

• A61K 31/198 - Alpha-amino-acides, p. ex. alanine ou acide édétique [EDTA]
• A61K 31/205 - Sels d'addition d'acides organiques avec des aminesSels d'ammonium quaternaire internes, p. ex. bétaïne, carnitine
• A61K 31/59 - Composés contenant le système cyclique du 9,10-séco-cyclopenta[a]hydrophénanthrène
• A61P 19/00 - Médicaments pour le traitement des troubles du squelette

Produits et services

RNA interference technology research; drug discovery services; pharmaceutical research and development; scientific research in the field of pharmacy; technical research in the field of pharmaceutical studies; pharmaceutical drug development services; providing information on the testing, inspection and research of medical products; clinical trials; laboratory research services relating to dermatology; testing, inspection and research services in the fields of pharmaceuticals, cosmetics and foodstuffs.

Produits et services

RNA interference technology research; drug discovery services; pharmaceutical research and development; scientific research in the field of pharmacy; technical research in the field of pharmaceutical studies; pharmaceutical drug development services; providing information on the testing, inspection and research of medical products; clinical trials; laboratory research services relating to dermatology; testing, inspection and research services in the fields of pharmaceuticals, cosmetics and foodstuffs.

Abrégé

Provided is a composition for preventing, improving, or treating muscular disorders including sulfonamide-based compounds or salts thereof. According to the present disclosure, the sulfonamide-based compounds or salts thereof may prevent inhibition of differentiation of myoblasts by regulating the expression of PHF20 and YY1. Accordingly, since the composition may prevent or alleviate muscle loss, promote muscle regeneration, and improve muscle exercise function, balance ability, and grip strength recovery ability through increased muscles and changes in ratio of muscle fibers, the composition may be effectively used for therapeutic agents, foods, or feeds for preventing, improving or treating muscle disorders, and improving muscle functions or muscle mass.

Classes IPC  ?

• A61K 31/505 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime
• A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire

Abrégé

The present invention relates to a function of PHF20 (PHD finger protein 20) in a myogenic differentiation mechanism and, more particularly, to a use of a PHF20 gene expression inhibitor or a PHF20 protein activity inhibitor. The PHF20 gene expression inhibitor or the PHF20 protein activity inhibitor according to the present invention promotes muscle differentiation in vitro and in vivo, and thus can be utilized in various ways in the field of prevention, improvement or treatment of diseases caused by muscle loss.

Classes IPC  ?

• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• A61K 9/20 - Pilules, pastilles ou comprimés
• A61K 9/48 - Préparations en capsules, p. ex. de gélatine, de chocolat
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A23L 33/00 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement
• A23L 33/13 - Acides nucléiques ou leurs dérivés
• A23K 20/153 - Acides nucléiquesLeurs hydrolysats ou dérivés

Abrégé

The present invention relates to a function of PHF20 (PHD finger protein 20) in a muscle differentiation mechanism and, more particularly, to a use of a PHF20 gene expression inhibitor or a PHF20 protein activity inhibitor. The PHF20 gene expression inhibitor or the PHF20 protein activity inhibitor according to the present invention promotes muscle differentiation in vitro and in vivo, and thus can be utilized in various ways in the field of prevention, improvement or treatment of diseases caused by muscle loss.

Classes IPC  ?

• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
• A23L 33/13 - Acides nucléiques ou leurs dérivés
• A23K 20/153 - Acides nucléiquesLeurs hydrolysats ou dérivés